AstraZeneca (AZN)
AstraZeneca (AZN) Stock Price, Analysis & Data
| Bid | 158.51 |
| Market Cap | 245.04B |
| Revenue (ttm) | 61.37B |
| Net Income (ttm) | 10.45B |
| Beta | 0.21 |
| EPS (ttm) | 6.68 |
| PE Ratio (ttm) | 23.65 |
| Forward PE | 13.64 |
| P/B (ttm) | 4.87 |
| P/S (ttm) | 3.99 |
| Earnings Date | Oct 30, 2026 |
| Ask | 158.58 |
| Volume | 3,303,184 |
| Avg. Volume (20D) | 2,740,651 |
| Open | 157.68 |
| Previous Close | 158.75 |
| Day's Range | 157.12 - 159.02 |
| 52-Week Range | 145.80 - 212.71 |
| Analyst | Strong Buy |
| Price Target | 214.5 (35.76%) |
| Dividends | $3.2 (2.01%) |
| Ex-Dividend Date | Aug 7, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormin...
Financial Performance
In 2025, AstraZeneca's revenue was 58.74B, an increase of 8.63% compared to the previous year's 54.07B. Earnings were 10.22B, an increase of 45.34%.
Financial StatementsAnalyst Forecast
According to 10 analyst ratings, the average rating for AZN stock is "Strong Buy". The 12-month stock price forecast is 214.5, which is upside of 35.76% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
